GNI Group Ltd. (TYO:2160)

Japan flag Japan · Delayed Price · Currency is JPY
3,385.00
+15.00 (0.45%)
Apr 20, 2026, 9:00 AM JST
Market Cap187.66B +69.2%
Revenue (ttm)26.84B +13.7%
Net Income-4.24B
EPS-80.90
Shares Out55.69M
PE Ration/a
Forward PE67.81
Dividendn/a
Ex-Dividend Daten/a
Volume62,300
Average Volume1,122,820
Open3,380.00
Previous Close3,370.00
Day's Range3,380.00 - 3,385.00
52-Week Range1,782.00 - 4,410.00
Beta1.31
RSI58.28
Earnings DateMay 15, 2026

About GNI Group

GNI Group Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of pharmaceuticals and biomaterials in Japan, China, and the United States. It operates in two segments, Pharmaceutical Business and Medical Equipment Business. The company offers ETUARY for the treatment of idiopathic pulmonary fibrosis; H-GENIN Crush-Mix for the treatment of bone defects; AltiPly for the treatment of acute and chronic wounds; and orthobiologics products. It also develops ETUARY which is in Phase III clinical trial for... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 990
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 2160
Full Company Profile

Financial Performance

Financial Statements